Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has secured “several hundreds of millions of yuan” ($14 million) in a funding round participated by local investment firm Tsing Song Capital.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
